Table S2 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

作者：James J. Harding, Ralf‐Dieter Hofheinz, Elena Élez, Yasutoshi Kuboki, Drew Rasco, Michael Cecchini, Lin Shen, Min He, Shorena Archuadze, Niraj Chhaya, Franziska Haderk, Lisa Mészáros, Stefan Wölke, Tetsuya Katakabe, Robert M. Lorence, Eric Van Cutsem, Scott Kopetz, Shubham Pant · 年份：2026 · DOI：10.1158/2767-9764.32700227 · 研究领域：Cancer Immunotherapy and Biomarkers、Monoclonal and Polyclonal Antibodies Research、HER2/EGFR in Cancer Research

<p>Full criteria for DLTs following treatment with BI 905711 as A) monotherapy (NCT04137289) or B) combination therapy (NCT05087992). Any of the following AEs were classified as DLTs, unless unequivocally due to underlying malignancy or an extraneous cause.</p>